JMJD1A Knockdown Reduces the Level of AR-V7 in Prostate Cancer Cells.

JMJD1A is a key AR coactivator in prostate cancer cells (15, 16). To examine the effect of androgens on JMJD1A and AR, we switched CWR22Rv1 prostate cancer cells (hereafter called Rv1 cells) to growth media containing 5% charcoal-stripped FBS (which has low androgen levels) and supplemented the media with either 5 μM antiandrogen enzalutamide (to maximally block androgenic action) or 1 nM synthetic androgen R1881 (to restore androgens to physiological levels). The former mimics androgen deprivation conditions, while the latter reflects normal androgen conditions. We found that protein levels of JMJD1A and AR-FL in Rv1 cells were not affected irrespective of the androgen conditions (Fig. 1A). Interestingly, although knockdown of JMJD1A in Rv1 cells had little effect on the protein levels of AR-FL, we found reduced levels of a protein band at 80 kDa, which is consistent with the size of AR-Vs (Fig. 1A). Using an AR-V7 specific antibody, Western blot analysis demonstrated that JMJD1A knockdown indeed reduced the protein levels of AR-V7 in Rv1 cells (Fig. 1A). Furthermore, qRT-PCR analysis showed that JMJD1A knockdown in Rv1 cells reduced mRNA levels of AR-V7, but not AR-FL, under either androgen-deprived or normal conditions (Fig. 1B).

• Download figure
• Open in new tab
• Download powerpoint

Fig. 1.

(A) Rv1 cells were transduced with pLKO.1 control or JMJD1A shRNAs for 24 h. Then, cells were maintained in growth media that contained 5% charcoal-stripped-FBS supplemented with either enzalutamide (Enza; 5 μM) or R1881 (1 nM). After 24 h, cell lysates were collected for Western blot analyses using the indicated antibodies. (B) Rv1 cells described in A were analyzed by qRT-PCR for transcripts of JMJD1A, AR-V7, or AR-FL. (C) LN95 cells (pLKO.1 or JMJD1A-knockdown) were treated and analyzed by qRT-PCR as described in A and B. (D) VCaP cells (pLKO.1 or JMJD1A-knockdown) were treated and analyzed by qRT-PCR as described in A and B. In B–D, the comparison with statistical significance (pLKO.1 vs. shJMJD1A) is indicated with an asterisk (**P < 0.01, *P < 0.05; ANOVA). (E) Immunohistochemistry staining of JMJD1A or AR-V7 was performed on prostate cancer TMA. The staining was developed with DAB (brown) and counterstained with hematoxylin (blue). Shown are representative images of high (Upper) and low (Lower) levels of JMJD1A or AR-V7 staining. (F) Quantification of JMJD1A or AR-V7 staining of prostate cancer TMA (n = 40). The staining of JMJD1A or AR-V7 was scored as 3 (strong), 2 (moderate), 1 (weak), or 0 (none). Scores of 3 or 2 were defined as high, and scores of 1 or 0 were defined as low. The Mann–Whitney U test was used for statistical analysis (P < 0.01).

LN95 and VCaP are two other prostate cancer cell lines known to express AR-V7, albeit at lower levels than Rv1 cells (Fig. S1A). Similar to our findings with Rv1 cells, JMJD1A knockdown in LN95 cells reduced mRNA levels of AR-V7, but not AR-FL, under both normal and androgen-deprived conditions (Fig. 1C). Unlike Rv1 or LN95 cells, mRNA levels of both AR-FL and AR-V7 were up-regulated in VCaP cells upon androgen deprivation (Fig. 1D), likely due to the transcriptional up-regulation of AR pre-mRNA in this cell line (22, 23). Nonetheless, JMJD1A knockdown in VCaP cells reduced mRNA levels of AR-V7, but not AR-FL, under either androgen deprivation or normal conditions (Fig. 1D). Taken together, these results indicate that JMJD1A promotes the expression of AR-V7, but not AR-FL, in prostate cancer cells known to express AR-V7.

To confirm the relevance of our findings to human prostate cancer, we evaluated the expression of JMJD1A and AR-V7 in a human prostate cancer tissue microarray (TMA) containing tumor samples of Gleason grades 3–5. JMJD1A and AR-V7 staining revealed primarily nuclear localization, but varying degrees of cytoplasmic staining of both proteins were also observed in some samples (Fig. 1E). Based on the relative staining intensity, we defined AR-V7 staining as either high (strong or moderate) or low (weak or none). JMJD1A staining was likewise defined as either high or low. Approximately 69.2% of JMJD1A-high tumors exhibited high staining of AR-V7, whereas only 16.7% of JMJD1A-low tumors exhibited high staining of AR-V7, with the majority (83.3%) stained at low intensity (Fig. 1F). These results indicate that JMJD1A may also promote the expression of AR-V7 in a subset of human prostate cancer tissues.

We previously reported that JMJD1A knockdown reduced levels of c-Myc in prostate cancer cells (15). To evaluate the possible involvement of c-Myc in modulating AR-V7 expression, we knocked down c-Myc in Rv1, LN95, and VCaP cells but found no change in AR-V7 mRNA levels (Fig. S1B). This indicates that c-Myc does not affect AR-V7 expression in these prostate cancer cell lines.

JMJD1A Promotes the Expression of Select AR Targets Through AR-V7.

JMJD1A is known to interact with and coactivate AR-FL in prostate cancer cells (13, 15). To assess if JMJD1A also interacts with AR-V7, we coexpressed myc-JMJD1A with either Flag-tagged AR-FL or AR-V7 in 293T cells and performed immunoprecipitation studies using anti-Flag M2 beads. Myc-JMJD1A coprecipitated with Flag-AR-FL, but not with Flag-AR-V7 (Fig. 2A), indicating that JMJD1A does not directly interact with AR-V7, and thus may not function as its coactivator. Of note, AR-FL and AR-V7 were shown to regulate the expression of both common and unique AR targets (4, 11, 12). If this were true, we reasoned that restoration of AR-V7 expression in JMJD1A-knockdown Rv1 cells should be able to rescue expression of AR targets that depend on AR-V7. To determine the dependency of AR targets on AR-FL or AR-V7, we knocked down AR-FL using shRNA that targeted the AR LBD domain and AR-V7 using shRNA that targeted the AR-V7 3′-UTR. Western blot and qRT-PCR analysis showed that levels of AR-FL or AR-V7 in Rv1 cells were efficiently and specifically knocked down by the respective shRNAs (Fig. 2B and Fig. S2A). As another control, AR-FL or AR-V7 shRNAs showed no effect on the mRNA level of AR-V1, another form of AR variant (Fig. S2A). Of note, knockdown of AR-V7 significantly reduced the level of AR-Vs (Fig. 2B), indicating that AR-V7 is the major form of AR-Vs in Rv1 cells. We next performed qRT-PCR analysis on a panel of well-characterized AR targets that include KLK3, NKX3.1, SLC45A3, FKBP5, NDRG1, SREBF1, STEAP1, and STEAP2. In Rv1 cells, the sample AR targets can be categorized into three groups (Fig. 2C and Fig. S2B): (i) AR targets, such as NKX3.1, KLK3, SLC45A3, or STEAP2, depend on AR-FL in normal androgen conditions but become dependent on AR-V7 under androgen-deprived conditions; (ii) AR targets, such as FKBP5, NDRG1, or STEAP1, depend on both AR-FL and AR-V7 in normal androgen conditions but depend mainly on AR-V7 under androgen-deprived conditions; and (iii) AR targets, such as SREBF1, are only dependent on AR-V7 under either normal or androgen-deprived conditions. Therefore, we chose NKX3.1, FKBP5, and SREBF1 as representative examples of each of the three AR target groups regulated by AR-FL and/or AR-V7 in Rv1 cells. We restored AR-V7 expression in JMJD1A-knockdown Rv1 cells to the control levels (Fig. 2D) and examined expression of representative AR targets by qRT-PCR (Fig. 2E). Under androgen deprivation conditions, reexpression of AR-V7 in JMJD1A-knockdown Rv1 cells rescued expression of NKX3.1, FKBP5, and SREBF1 (Fig. 2E), consistent with the dependency of these AR targets on AR-V7 in the absence of androgen (Fig. 2C). In contrast, under normal androgen conditions, reexpression of AR-V7 in the JMJD1A-knockdown Rv1 cells fully rescued SREBF1 expression, partly rescued FKBP5 expression, but had no effect on NKX3.1 expression (Fig. 2E). These data are consistent with the dependency of SREBF1 on AR-V7, partial dependency of FKBP5 on AR-V7, and dependency of NKX3.1 on AR-FL in the presence of androgens (Fig. 2C). Taken together, the above results demonstrate that JMJD1A-dependent expression of AR-V7 in Rv1 cells promotes expression of AR targets that rely on AR-V7.

• Download figure
• Open in new tab
• Download powerpoint

Fig. 2.

(A) Flag-tagged AR-V7 or AR-FL was cotransfected with myc-JMJD1A in 293T cells for 24 h. Cell lysates were then subjected to immunoprecipitation (IP) with anti-Flag M2 beads. Bound proteins were analyzed by Western blotting with myc or Flag antibodies. (B) Rv1 cells were transduced with pLKO.1 control, AR-V7 shRNA, or AR-FL shRNA. After 48 h, cell lysates were analyzed by Western blotting with the AR antibody (N-20) that recognizes the AR N-terminal region. (C) Rv1 cells described in B were maintained in growth media that contained 5% charcoal-stripped FBS supplemented with enzalutamide (Enza; 5 μM) or R1881 (1 nM). After 24 h, RNAs were collected and analyzed by qRT-PCR for transcripts of representative AR target genes that include NKX3.1, FKBP5, and SREBF1. (D) AR-V7 was reexpressed in JMJD1A-knockdown Rv1 cells via lentiviral transduction (shJMJD1A+AR-V7). Cell lysates were analyzed by Western blotting with antibodies against AR-V7 or JMJD1A. (E) Rv1 cells (pLKO.1, shJMJD1A, or shJMJD1A+AR-V7) were treated and analyzed by qRT-PCR as described in C. In C and E, the comparison with statistical significance is indicated with an asterisk (**P < 0.01, *P < 0.05; ANOVA).

AR-V7 Is a Downstream Effector of JMJD1A in Rv1 Cells.

To assess the effect of AR-V7 on JMJD1A-dependent cell growth, we evaluated colony formation by JMJD1A-knockdown Rv1 cells upon restoring the expression of AR-V7 in these cells (shJMJD1A+AR-V7), as described in Fig. 2D. The Rv1 cells were allowed to form colonies in the presence or absence of androgen. Compared with the pLKO.1 control, JMJD1A-knockdown Rv1 cells showed about a fivefold reduction in colony formation (Fig. 3 A and B). Reexpression of AR-V7 in JMJD1A-knockdown Rv1 cells partially increased their ability to form colonies (Fig. 3 A and B). Comparable results were seen for Rv1 cells grown in the presence or absence of androgen, although the presence of androgen slightly increased colony formation (Fig. 3 A and B).

• Download figure
• Open in new tab
• Download powerpoint

Fig. 3.

(A and B) Rv1 cells (pLKO.1, shJMJD1A, or shJMJD1A+AR-V7) were seeded at low density and maintained for 3 wk in 5% charcoal-stripped FBS media with or without 1 nM R1881 supplement. Colony number (>100 μm in diameter) was scored after 3 wk. Representative images of colonies are shown in A, and the colony number per high-power field is shown in B. +R1881, P < 0.001 for any pairwise comparison (ANOVA); −R1881, P < 0.001 for any pairwise comparison (ANOVA). (C) Rv1 cells (pLKO.1, shJMJD1A, or shJMJD1A+AR-V7) were injected s.c. into immune-deficient NSG mice (n = 20 per group). After 1 wk, half of the mice in each group were castrated, while the other half were sham-castrated. The xenograft tumors were collected, and tumor weight was measured 2 wk later. For sham conditions, P < 0.001 for any pairwise comparison (ANOVA); for castration conditions, P < 0.001 for any pairwise comparison (ANOVA). (D) Example staining of Ki67 (Upper) and active caspase-3 (Lower) on tumor sections derived from the indicated Rv1 cells. The staining was developed by DAB (brown) and counterstained by hematoxylin (blue). The image width is 0.5 mm. (E) Percentage of Ki67-positive cells per field on the staining described in D. P < 0.01 for shJMJD1A vs. shJMJD1A+AR-V7 (ANOVA); P < 0.001 for other pairwise comparisons (ANOVA). (F) Number of positive cells for active caspase-3 per field on staining described in D. P < 0.001 for pLKO.1 vs. shJMJD1A (ANOVA); P < 0.01 for other pairwise comparisons (ANOVA).

To further test the role of AR-V7 in JMJD1A-dependent tumor growth in vivo, we used a xenograft prostate tumor model in which Rv1 cells were injected s.c. into immune-deficient NSG mice. Compared with control cells, JMJD1A-knockdown Rv1 cells showed an ∼13-fold reduction in tumor weights in the control mice, with no tumor formation in castrated mice (Fig. 3C). Reexpression of AR-V7 in JMJD1A-knockdown Rv1 cells partly rescued xenograft tumor formation in both control and castrated mice (Fig. 3C). We next performed immunohistochemistry staining for the proliferation marker Ki67 and the apoptosis marker active caspase-3 on xenograft tumor sections. JMJD1A knockdown reduced the percentage of Ki67-positive cells, concomitant with an increased number of cells positive for active caspase-3 (Fig. 3 D–F). These results suggest that JMJD1A knockdown inhibits proliferation and promotes apoptosis in xenograft prostate tumors. In contrast, the patterns of Ki67 and active caspase-3 staining detected in JMJD1A-knockdown tumors were partially reversed after AR-V7 reexpression (Fig. 3 D–F). Overall, these findings confirmed that AR-V7 could function as a downstream effector of JMJD1A to drive the growth and survival of prostate cancer cells under normal or androgen-deprived conditions.

JMJD1A Promotes Splicing of AR-V7 Through HNRNPF.

In contrast to the splicing of AR-FL mRNA, which uses the 3′ splice site in front of exon 4, the splicing of AR-V7 mRNA uses an alternative 3′ splice site in front of the cryptic exon 3b (Fig. 4A), which results in translation of an AR protein with a truncated C terminus (4, 5). To determine if JMJD1A could affect AR-V7 mRNA splicing, we used an AR-V7 minigene reporter plasmid, in which exon 3b and its flanking ∼400-bp nucleotide sequence were inserted between exons 3 and 4 of the human AR gene (23). The plasmid was transfected into AR-negative PC3 prostate cancer cells (pLKO.1 control or JMJD1A knockdown), followed by qRT-PCR analysis of the spliced product reflecting AR-V7 (splicing between exon 3 and 3b) or AR-FL (splicing between exon 3 and 4) (Fig. 4A). We found that JMJD1A knockdown reduced the splicing of AR-V7 but had no apparent effect on the splicing of AR-FL (Fig. 4B). These results indicate that JMJD1A promotes splicing of AR-V7 mRNA.

• Download figure
• Open in new tab
• Download powerpoint

Fig. 4.

(A) Diagram of the AR minigene reporter. Exons, introns, and PCR primers used to detect exon splicing are indicated in the diagram. Splicing between exons 3 and 3b reflects formation of AR-V7 mRNA, which can be detected by the F1/R1 primer pair. Splicing between exons 3 and 4 reflects formation of AR-FL mRNA, which can be detected by the F2/R2 primer pair. (B) PC3 cells (pLKO.1 or shJMJD1A) were transfected with the AR minigene reporter. After 72 h, RNAs were isolated and analyzed by qRT-PCR using the F1/R1 or F2/R2 primer pair, which reflects the levels of AR-V7 or AR-FL, respectively. (C) Rv1 cells were transduced with pLKO.1 control or HNRNPF shRNA. After 48 h, RNAs were isolated and analyzed by qRT-PCR for HNRNPF or AR-V7. (D) Flag-tagged HNRNPF or HNRNPH was cotransfected with myc-JMJD1A in 293T cells. Cell lysates were subjected to immunoprecipitation (IP) with anti-Flag M2 beads. Bound proteins were analyzed by Western blotting with myc or Flag antibodies. (E) Rv1 cells were transduced with pLKO.1 control, HNRNPF, or HNRNPH shRNAs. After 48 h, cell lysates were analyzed by Western blotting with AR antibody (N-20, Top) or other indicated antibodies. (F) Rv1 cells (pLKO.1 or HNRNPF-knockdown) were maintained in growth media containing 5% charcoal-stripped FBS supplemented with either enzalutamide (Enza; 5 μM) or R1881 (1 nM) for 24 h. RNAs were isolated and analyzed by qRT-PCR for transcripts of representative AR target genes. (G) PC3 cells (pLKO.1 or HNRNPF-knockdown) were transfected with the AR minigene reporter. After 72 h, RNAs were isolated and analyzed by qRT-PCR to detect reporter levels of AR-V7 or AR-FL, respectively. In B, C, F, and G, the comparison with statistical significance is indicated with an asterisk (**P < 0.01, *P < 0.05; t test).

We next addressed the mechanism by which JMJD1A promotes the splicing of AR-V7. We first hypothesized that JMJD1A may promote the expression of factors that play a role in AR-V7 splicing. We reexamined our previous profiling array data (GSE70498) on the JMJD1A-knockdown Rv1 cells (15) and searched the known RNA splicing regulators whose expression was regulated by JMJD1A. We chose SYF2, SRSF7, PHF5A, RBFOX2, SREK1, RAVER2, and ESRP1 for further analysis because they were among the highly down-regulated genes in the JMJD1A-knockdown cells and are known to regulate mRNA splicing. However, individual knockdown of these splicing regulators in Rv1 cells showed no effect on AR-V7 mRNA levels (Fig. S3A). This excluded the involvement of these seven splicing regulators examined, although we could not exclude the possible involvement of other JMJD1A-dependent genes in splicing events that generate AR-V7. We next tested a second hypothesis that JMJD1A may interact with a splicing regulator to promote AR-V7 splicing. Mass spectrometry analysis of proteins that coprecipitated with Flag-JMJD1A in Rv1 cells revealed nine candidate proteins (Table S1), among which HNRNPF, PTBP1, and YBX1 were known to regulate mRNA splicing. We found that knockdown of HNRNPF, but not PTBP1 or YBX1, reduced the levels of AR-V7 mRNA in Rv1 cells (Fig. 4C and Fig. S3B). Consistent with the MS results, we found that myc-JMJD1A coprecipitated with Flag-HNRNPF, but not Flag-HNRNPH, which is a close relative of HNRNPF (Fig. 4D). Knockdown of HNRNPF in Rv1 cells reduced AR-V7 protein levels but had little effect on those of AR-FL (Fig. 4E). In contrast, knockdown of HNRNPH had little effect on either AR-V7 or AR-FL (Fig. 4E). The qRT-PCR analysis revealed that the effects of HNRNPF knockdown with respect to the expression of sample AR targets (Fig. 4F) resembled those of AR-V7 knockdown (Fig. 2C). Similarly, the AR-V7 minigene reporter assay demonstrated that HNRNPF knockdown reduced splicing of AR-V7, but not AR-FL (Fig. 4G). We also examined the staining of HNRNPF on 36 specimens of human prostate cancer tissue. HNRNPF displayed strong nuclear staining in all of the samples (Fig. S4), indicating that HNRNPF is highly expressed in prostate cancer.

HNRNPF binds to the G-tract sequences that contain at least three consecutive G’s (G-triplet) on pre-mRNA to regulate splicing (24). Within a 200-bp region around the 3′ splice site of exon 3b, there are five G-tracts in the downstream exon 3b sequence (Fig. 5A) but none in the upstream intron sequence. To determine if AR-V7 splicing required any of the five G-tracts, we mutated each G-tract sequence in the AR-V7 minigene reporter. Mutation of the first G-tract adjacent to the 3′ splice site reduced AR-V7 splicing, whereas mutation of the other G-tracts had no effect (Fig. 5B). To determine if HNRNPF could bind to the identified G-tract, we synthesized an RNA oligo representing either a wild-type (WT) or mutant G-tract sequence for RNA pull-down experiments. We found that purified HNRNPF could be pulled down by the WT oligo (Fig. 5C, lane 3), whereas pull-down of HNRNPF by the mutant oligo was reduced (Fig. 5C, lane 4). These results indicate that HNRNPF binds to the G-tract sequence within the RNA oligo. Purified JMJD1A alone was not pulled down by the WT oligo (Fig. 5C, lane 1); however, pull-down of JMJD1A by the WT RNA oligo was detected after the addition of HNRNPF (Fig. 5C, lane 5). Similarly, the mutant RNA oligo showed a reduced capability to pull down JMJD1A in the presence of HNRNPF (Fig. 5C, lane 6). These results indicate that JMJD1A may bind to the G-tract sequence through HNRNPF. Interestingly, addition of JMJD1A slightly increased the pull-down of HNRNPF by the WT oligo (Fig. 5C, lane 3 vs. lane 5), suggesting that JMJD1A–HNRNPF interaction may enhance the binding of HNRNPF to the G-tract sequence. Taken together, these data reveal that HNRNPF, an mRNA splicing factor that interacts with JMJD1A, plays a role in AR-V7 splicing.

• Download figure
• Open in new tab
• Download powerpoint

Fig. 5.

(A) Partial sequence of intron 3 (bold) and exon 3b from the AR gene. The first three G-tracts (underlined) were individually mutated in the AR minigene reporter (M1 to M3), while the last two G-tracts were simultaneously mutated (M4 + M5). (B) PC3 cells were transfected with the AR minigene reporter (WT or G-tract mutants). After 72 h, RNAs were isolated and analyzed by qRT-PCR to detect reporter levels of AR-V7 or AR-FL, respectively. (C) Purified Flag-HNRNPF and/or Flag-JMJD1A was incubated with RNA oligo-conjugated beads (WT or G-tract mutant). The beads were washed, and bound proteins were analyzed by Western blotting using anti-Flag antibodies.

JMJD1A Promotes the Recruitment of HNRNPF and Spliceosome Component to Exon 3b of AR Pre-mRNA.

The RNA pull-down experiments indicate that JMJD1A and HNRNPF can bind to the G-tract sequence in vitro. To determine if JMJD1A and HNRNPF could also bind to the same site in the AR pre-mRNA, we performed RNA immunoprecipitation (RIP) assays. We immunoprecipitated JMJD1A or HNRNPF from the lysates of Rv1 cells, and the bound RNAs were isolated for qRT-PCR analysis using two sets of primers. The first set of primers targeted the P1 region (i.e., the 3′ splice site of exon 3b) of AR pre-mRNA, and the second set of primers targeted the P2 region (i.e., the 3′ splice site of exon 4) (Fig. 6A). The RIP assays showed that HNRNPF and JMJD1A were both enriched in the P1, but not the P2, region of AR pre-mRNA (Fig. 6 B and C), which is consistent with the function of JMJD1A and HNRNPF to splice AR-V7, but not AR-FL. HNRNPF knockdown had no effect on the levels of JMJD1A (Fig. S5A) but reduced JMJD1A enrichment at the P1 region (Fig. 6C). Again, these results are consistent with the result of RNA pull-down experiments showing that JMJD1A likely binds to this region through an interaction with HNRNPF. JMJD1A knockdown also had no effect on HNRNPF levels (Fig. S5B). However, the RIP assays showed that JMJD1A knockdown strongly reduced HNRNPF enrichment at the P1 region (Fig. 6B), suggesting that JMJD1A plays a key role in the binding of HNRNPF to this region of AR pre-mRNA.

• Download figure
• Open in new tab
• Download powerpoint

Fig. 6.

(A) Diagram showing primers used to amplify the P1 or P2 region of AR pre-mRNA in the RIP assays. (B) Rv1 cells (control, JMJD1A-knockdown, or HNRNPF-knockdown) were subjected to RIP assays using HNRNPF antibodies (Ab). Precipitated RNAs were isolated and analyzed by qRT-PCR with primers that amplified the P1 or P2 region. Data were calculated as the percentage of input and plotted as fold change over control (Ab). (C) Rv1 cells (control, JMJD1A-knockdown, or HNRNPF-knockdown) were subjected to RIP assays with JMJD1A Ab. The results were analyzed as described in B. (D) Rv1 cells (control, JMJD1A-knockdown, or HNRNPF-knockdown) were subjected to RIP assays using U2AF65 Ab. The results were analyzed as described in B.

We next tested whether JMJD1A and HNRNPF could affect the recruitment of spliceosome components to the 3′ splice site in front of exon 3b. We performed the RIP assay using antibodies to U2AF65, which is one of the spliceosome components associated near the 3′ splice site. We found that knockdown of either JMJD1A or HNRNPF reduced U2AF65 enrichment at the P1 region but had no effect on its enrichment at the P2 region (Fig. 6D). As a control, knockdown of HNRNPF or JMJD1A showed no effect on U2AF65 levels (Fig. S5 A and B). To determine if HNRNPF and JMJD1A can directly recruit U2AF65, we purified U2AF65 for the in vitro RNA pull-down experiments as described in the legend for Fig. 5C. As expected, the RNA oligo, which lacks the U2AF65 binding site, failed to directly pull down U2AF65 (Fig. S5C, lane 1). In contrast, addition of HNRNPF led to the pull-down of U2AF65 by WT, but not the G-tract, mutant oligo (Fig. S5C, lane 3 vs. lane 4). These results suggest that U2AF65 may associate with the RNA oligo through HNRNPF. Addition of JMJD1A further increased the pull-down of both HNRNPF and U2AF65 by the RNA oligo (Fig. S5C, lane 3 vs. lane 5). Taken together, the results of RIP and RNA pull-down experiments indicate that JMJD1A–HNRNPF interaction promotes the recruitment of a spliceosome component to the 3′ splice site region of exon 3b on AR pre-mRNA.

JMJD1A Recruits HNRNPF to Exon 3b of AR Genomic DNA.

Some splicing factors can associate with chromatin to facilitate the cotranscriptional mRNA splicing (25, 26). Because JMJD1A is a histone demethylase that can associate with chromatin, we determined to test if JMJD1A and HNRNPF associate with the chromatin region of the AR gene. We performed chromatin immunoprecipitation (ChIP) assays on the chromatin fragments prepared from Rv1 cells using antibodies of JMJD1A, HNRNPF, or H3K9me2. The precipitated DNA fragments were analyzed by qPCR using the same set of primers that were used for the RIP assay (Fig. 7A). The ChIP assays showed that HNRNPF and JMJD1A were enriched at the P1, but not the P2, region (Fig. 7 B and C), indicating their chromatin association near the 3′ splice site of exon 3b. JMJD1A knockdown reduced the enrichment of HNRNPF at the P1 region similar to that seen upon HNRNPF knockdown (Fig. 7B), indicating that JMJD1A may mediate the binding of HNRNPF with this chromatin region. In contrast, HNRNPF knockdown showed no effect on the enrichment of JMJD1A at the P1 region (Fig. 7C), indicating that HNRNPF does not affect the chromatin binding of JMJD1A. The ChIP assays also revealed the enrichment of H3K9me2 marks at the P1, but not the P2, region, and the increased level of H3K9me2 at the P1 region upon JMJD1A knockdown (Fig. 7D). Together, these results indicate that H3K9me2 may recruit JMJD1A, and thus HNRNPF, to exon 3b of AR genomic DNA.

• Download figure
• Open in new tab
• Download powerpoint

Fig. 7.

(A) Diagram showing primers used to amplify the P1 or P2 region of the AR gene in the ChIP assays. (B) Rv1 cells (control, JMJD1A-knockdown, or HNRNPF-knockdown) were subjected to ChIP assays using HNRNPF antibodies (Ab). Precipitated chromatin fragments were isolated and analyzed by qPCR with primers that amplified the P1 or P2 region. Data were calculated as the percentage of input. (C) Rv1 cells (control, JMJD1A-knockdown, or HNRNPF-knockdown) were subjected to ChIP assays using JMJD1A Ab. The results were analyzed as described in B. (D) Rv1 cells (control, JMJD1A-knockdown, or HNRNPF-knockdown) were subjected to ChIP assays using H3K9me2 Ab. The results were analyzed as described in B.